PerkinElmer to Acquire Horizon Discovery Group for a Total of $368 Million

November 3, 2020
Pharmaceutical Technology Editors

PerkinElmer will have the opportunity to strengthen its portfolio of automated life sciences discovery and applied genomics solutions by including Horizon’s gene editing and gene modulation tools.

PerkinElmer announced on Nov. 2, 2020 that it is acquiring Horizon Discovery Group, a UK-based cell engineering company, for a total of $368 million.

Through the acquisition, PerkinElmer will have the opportunity to strengthen its portfolio of automated life sciences discovery and applied genomics solutions by including Horizon’s gene editing and gene modulation tools, a PerkinElmer press release said. Additionally, the deal will enhance PerkinElmer’s partnerships with academic and pharma/biopharma scientists by helping to address today’s research challenges.

“One of the key fundamentals for molecular research and drug discovery is being able to knock down a gene or function and explore the results to discover actionable insights and new clinical trial candidates faster,” said Prahlad Singh, president and CEO, PerkinElmer, in the press release. “We’re excited to team up with Horizon to not only add CRISPR and RNAi capabilities into our existing portfolio, but also to leverage our combined life sciences screening and applied genomics solutions to help propel the next phase of cell and gene research for precision medicine. PerkinElmer leads with science and creates total solutions to bring today’s leading innovations together for our customers, while also working at the cutting edge of what’s next.”

Source: PerkinElmer